Mikart, LLC, a contract development and manufacturing organization (CDMO), has entered into a collaboration agreement with Nano PharmaSolutions, Inc. (NPS), a nanotechnology company that has a proprietary NanoTransformer that enhances the solubility of active pharmaceutical ingredients (API).

“We are excited to bring this new technology from preclinical stage to a GMP clinical phase manufacturing environment,” said Nazar Elkarim, vice president of pharmaceutical development services at Mikart. “This differentiated, solvent-free, nano-granulation process for drug development and manufacturing provides our customers with an alternative solubility enhancement technology.”

Kay Olmstead, CEO at NPS, said, “Nano PharmaSolutions is excited for this collaboration which will provide us with GMP manufacturing capabilities for development of nanomedicines, using our NanoTransformer technology at Mikart’s facility.”